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Background: This study aimed to review translational studies focusing on third molar removal surgeries through 
a systematic analytical approach. 
Material and Methods: A PROSPERO-registered systematic review (CRD42017060455) was conducted following 
the PRISMA statement to summarize current knowledge on gene expression in third molar surgeries. A search 
was performed in PubMed’s Medline and Scopus databases, without date or language restrictions, using the logi-
cal expression {[(Third molar) OR (preemptive) OR (cyclooxygenase inhibitors) OR (acute inflammation) AND 
(gene expression)]}. 
Results: All studies included in the analysis evaluated gene expression in a third molar extraction model, using 
the preemptive analgesia methodology in seven investigations. The sample analyzed was obtained from gingival 
tissue biopsy (n=4), blood (n=1), transudate (n=1) and gingival tissue biopsy/transudate (n=1). There were differ-
ences with respect to evaluated genes, drug protocol, sample studied, and method for evaluating gene expression. 
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Introduction
The evaluation of specific gene expression has been 
widely used as an important tool in studies in the field 
of dentistry, including translational investigations to de-
termine diagnostic approaches, as well as to evaluate 
pharmacology-based drug protocols commonly utilized 
in clinical situations (1,2). In addition, genetic analyses 
through observation of messenger RNA (mRNA) ex-
pression or the measurement of specific mediators such 
as cytokines have produced important findings that 
support a relationship between tissue damage, degree 
of inflammatory response, and onset of clinical related 
events such as pain and edema in surgical procedures 
for the removal of third molars (3-5).
Removal of third molars is an invasive procedure capa-
ble of triggering varying levels of pain and other related 
inflammatory events, which can significantly affect the 
patient’s quality of life (6). These factors have contrib-
uted to the routine use of third molar surgery as a use-
ful clinical model to analyse the efficacy of conventional 
prescribed analgesics and anti-inflammatory drugs in 
order to minimize the effects of inflammation arising 
from surgical intervention until the postoperative period 
(7,8). As pain and edema are expected following the sur-
gical procedure, it is predicted that these events, elicited 
by inflammation, would be correlated with gene-related 
increases of key pro-inflammatory cytokines released at 
the site of the injury, e.g. interleukin 1 beta (IL-1β) and 
tumor necrosis factor alpha (TNF-α). Indeed, these mark-
ers have been shown to have significantly increased lev-
els after the extraction of third molars (3) and are directly 
linked to cyclooxygenase isoform gene expression dur-
ing the inflammatory process (9).
Cyclooxygenase gene evaluation has attracted sub-
stantial interest due to its value in both the laboratory 
setting and clinical situations since the routine use of 
selective and non-selective COX-2 non-steroidal anti-
inflammatory drugs (NSAIDs) may be associated with 
different levels of COX expression, facilitating the test-
ing of these medicines for relief of third molar-related 
inflammatory symptoms (3,10). The use of methods for 
the quantification of COX expression following clini-
cal procedures under pharmacological analgesic and 
anti-inflammatory protocols should help to explain the 
influence of these drugs on pain variables and lead to 
significant improvements in treatment (10-12). 
Other genes besides COX isoforms have been studied in 
the field of third molar surgery as target genes during the 
inflammatory process (2). Recently, certain authors per-
formed quantitative analysis of gene expression in trans-
lational researches evaluating the effect of preoperative 
administration of different NSAIDs on the severity of 
clinical events related to inflammation in patients who 
underwent the surgical removal of third molars (12,13). 
Although the quantitative real-time polymerase chain 
reaction (RT-qPCR) is considered a standard method-
ology, widely used in experimental investigations (14), 
other methodologies have been proposed for evaluat-
ing gene expression in third molar surgeries in order to 
find correlations with postoperative clinical symptoms, 
such as pain and edema (11,13). However, an overview 
of these studies by means of a systematic analysis was 
not published to date. Systematic reviews are important 
approaches designed to investigate specific issues of 
scientific interest using clear, well defined, and rigorous 
methods (15). These studies characteristically involve a 
meticulous and comprehensive plan and search strategy, 
defined a priori, that aims to reduce bias by identifying, 
appraising, and synthesizing all pertinent studies on a 
certain topic (16,17). 
The scientific value of systematic reviews depends 
on several factors. Despite a standardized approach, 
some articles have historically suffered methodologi-
cal failures in relation to the structuring of the research. 
Consequently, both the “Preferred Reporting Items for 
Systematic Review and Meta-Analysis (PRISMA)” cri-
teria, available since 2009 (18), as well as the register 
of these studies at the web-based platform, the “In-
ternational prospective registry of systematic reviews 
(PROSPERO)”, accessible since 2011, have been adopt-
ed here in order to minimize inconsistencies and bias 
during the review process (15,19). The importance of 
obtaining adequate, objective data regarding COX gene 
expression in translational studies dictated the present 
PROSPERO-registered systematic review, based on 
standardized methodology and following the PRISMA 
guide recommendations.
Material and Methods 
-Protocol and Registration
A systematic review was conducted to summarize cur-
rent knowledge concerning gene expression recorded 
Conclusions: Third molar surgeries were found to be associated with different COX-related gene expression patterns. 
Although inflammatory events following the surgical procedure are associated with COX isoforms, data from pre-
emptive analgesia studies are scarce, especially from studies correlating gene expression and clinical parameters. In 
the future, from a clinical perspective, identifying the molecular targets of a drug based on individual gene expres-
sion may be helpful to delineate specific third molar, surgery-related, preemptive analgesia protocols.
Key words: Third molar, gene expression, preemptive analgesia, systematic review.
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in clinical studies involving the preemptive use of 
NSAIDs in third molar surgeries. This systematic re-
view was registered in the PROSPERO database and 
conducted following the PRISMA statements under the 
number 42017060455. 
-Information Sources and Search Strategy
The PICO strategy (Patient/Population: patients; Inter-
vention: preemptive analgesia for third molar removal; 
Comparison: gene expression; Outcome: studied vari-
ables) was used to formulate the initial question to be 
answered by this systematic review: “Is there evidence 
of variation of gene expression in patients who under-
went preemptive analgesia with NSAIDs during third 
molar surgeries?” 
In order to perform the search strategy, PubMed’s Med-
line, Scopus, and SciencDirect were used as electronic 
databases to retrieve articles without date or language 
limits. The systematic review was conducted on April 
10, 2017, and the computer network of the Federal Uni-
versity of Ceará (Brazil), School of Dentistry was used 
to perform the electronic data search. The algorithm 
used was: {[(Third molar) OR (preemptive) OR (cyclo-
oxygenase inhibitors) OR (acute inflammation) AND 
(gene expression)]}. 
Other sources were also used to include additional 
articles. A manual search of related journals was per-
formed, including: 1) Medicina oral patología oral y 
cirugia bucal, 2) The British journal of oral & maxillo-
facial surgery, 3) International journal of oral and max-
illofacial surgery, 4) The journal of craniofacial surgery, 
5) Journal of cranio-maxillo-facial surgery, 6) Journal 
of maxillofacial and oral surgery, 7) Journal of oral and 
maxillofacial surgery, 8) Anesthesia and analgesia, 9) 
Prostaglandins, leukotrienes, and essential fatty acids, 
10) Oral surgery, oral medicine, oral pathology and oral 
radiology, 11) Clinical pharmacology & therapeutics, 
12) British journal of pharmacology, 13) The clinical 
journal of pain, 14) British journal of rheumatology, 
15) European journal of pharmacology, 16) Pain, 17) 
Inflammation research, 18) The journal of pain, and 19) 
Anesthesiology. Reference lists obtained from the iden-
tified articles and relevant reviews on the subject also 
were checked for possible additional studies.
-Eligibility criteria
The inclusion criteria adopted in this review were: ar-
ticles without language or year of publication restric-
tions, clinical studies involving gene expression in oral 
surgery, and studies involving human beings. Exclu-
sion criteria, items not considered eligible for inclusion, 
were: case reports, case series, literature reviews, and 
editor’s notes. 
-Study selection and data collection process 
A two-phase selection of the articles was conducted. 
In Phase 1, two independent researchers (AFMA and 
CMSP) determined eligibility by reading titles and ab-
stracts of each identified study; subsequently, some ar-
ticles found in different databases were excluded on the 
basis of duplication. In Phase 2, the full text of eligible 
articles was assessed following the inclusion criteria. 
Any reviewer disagreements were resolved by consen-
sus with a third researcher (FWGC).
The researchers independently extracted the data using 
previously established criteria. Each selected study was 
analyzed and the following variables adopted for the 
systematic review were summarized when available: 
study origin, number of patients, sex, age, use of pre-
emptive analgesia therapy, studied drugs, type of mate-
rial collected for gene expression analysis, evaluation 
time, and quantitative data on the studied genes.
-Risk of bias in individual studies
The methodological validity of selected studies was 
assessed by two independent reviewers (AFMA and 
CMSP) using the Joanna Briggs Institute Meta Analysis 
of Statistics Assessment and Review Instrument (JBI-
MAStARI) as previously reported (20). The reviewers 
independently scored each data item as “yes”, “no”, 
“unclear” or “not applicable” and assessed the quality 
of each included study. A third author (FWGC) resolved 
any disagreement between the reviewers through dis-
cussion. Risk of bias was categorized as high (up to 49% 
scored “yes”), moderate (50–69% scored “yes”), and 
low (more than 70% scored “yes”).
-Synthesis of results
Data were imported into an Excel (Microsoft Corpo-
ration, Redmond, WA) spreadsheet which was used to 
calculate relative and absolute data frequencies.
Results
-Study selection
The article selection process is presented in Figure 1. 
The search strategy identified an initial 7,177 articles, of 
which 86 studies were found in more than one database 
(duplicates) and were removed. Of the remaining ar-
ticles, 7,076 were excluded because they did not discuss 
the topics adopted for investigation in the present study. 
Manual searches in related journals did not result in addi-
tion studies and the 15 remaining qualifying articles were 
completely read. Nine of these studies were excluded be-
cause they did not meet the eligibility criteria since they 
did not evaluate gene expression in third molar surgeries. 
Searches of the reference lists from the selected studies 
rendered two additional articles. Consequently, seven ar-
ticles were ultimately evaluated in this review. 
-Study characteristics
All of the selected studies originated from North Amer-
ica (USA), representing a total of 929 patients, with a 
predominance of males (69%), females (31%). The sub-
jects were mainly adults, with ages ranging from 16 
to 66 years and an approximate mean age of 25 years 
(Table 1). 
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Fig. 1. Flowchart showing the eligibility criteria for article selection adopted in the present study.
Author Origin Evaluated genes Drug protocol Sample studied Method







Blood Radioimmunoassay (PGE2) 
and enzyme immunoassay 
(TXB2)




None Gingival tissue RT-qPCR














Wang et al. 
2006
USA 1) MMP 1) Rofecoxib
2) Ibuprofen
3) Placebo
Gingival tissue Microarray and RT-qPCR









Gingival tissue Microarray and RT-qPCR























and enzyme immunoassay 
(TXB2)
Table 1. Characterization of the selected studies regarding year of publication, origin, evaluated genes, drug protocol, sample studied, and 
performed test.
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All of the articles analyzed gene expression in patients 
undergoing third molar surgery. The samples evaluated 
for this purpose were gingival tissue removed during 
the surgical procedure in five studies, n=722 patients 
(2,4,5,20,21), followed by blood analysis in one investi-
gation, n=104 patients (22), and gingival exudate analy-
sis in another study, n=103 patients (13). 
-Risk of bias within studies
As shown in Figure 2, the mean percentage of “yes” 
scores was 76.2±11.9, ranging from 77.8% to 88.9%. 
The risk of bias within studies was considered moder-
ate in two studies and low in five studies.
Results of individual studies
There was a preponderance of COX-2 selective NSAID 
treatments among the articles published in the field of 
the preemptive analgesia. The following drugs were 
used: rofecoxib, n=5 articles (2,4,21–23); ibuprofen,n=5 
Fig. 2. Critical appraisal checklist summary for randomized control/pseudo-randomized trials (JBI-MAS-
tARI).
articles (2,13,21–23); ketorolac, n=1 article (4); acet-
aminophen, n=1 article (4); indomethacin, n=1 article 
(23); celecoxib, n=1 article (13), and placebo, n=6 ar-
ticles (2,4,13,21–23). In all of these studies, methodolo-
gies were applied in order to obtain data about COX 
gene expression. A variety of methods were used and 
these are summarized in Table 1; three studies quanti-
fied gene expression by using RT-qPCR analysis and the 
remaining studies performed an indirect evaluation of 
the COX expression by analyzing related genes: throm-
boxane B2 (TXB2) (4,13,23), prostaglandin E2 (PGE2) 
(4,13,23), matrix metalloproteinase (MMP) (21), phos-
pholipase A2 (PLA), suppressors of cytokine signaling 
3 (SOCS), and interleukins 1 and 6 (IL-1 and IL-6, re-
spectively) (2,22).
Pain was the common clinical parameter evaluated as 
a primary outcome reflecting the inflammatory events 
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following surgical removal of third molars in these 
studies. Among these studies, pain was measured by 
means of visual analog scales (VAS) in four investiga-
tions (2,4,13,23), and the others only included a labora-
tory analysis without proper clinical observation. Pain 
was evaluated over different study periods or at certain 
time points, such as 0–6 h (n=1), 0–180 min (n=1), 2–4 
h and 48 h (n=1), or 24 h (n=1) postoperatively. In addi-
tion, VAS was used in two articles and scores ranging 
from 1 to 4 (mild, moderate, grave, and severe respec-
tively) were employed in the other studies.
When the pharmacological class of the studied NSAIDs 
was evaluated with respect to COX gene expression 
(2,4,21,22), it was observed that coxibs (rofecoxib and 
celecoxib) presented a significant selectivity related to 
COX-2, ranging from 5 to 500 times greater than other 
non-selective NSAIDs (ibuprofen, acetaminophen, and 
indomethacin) or placebo, being evaluated by RT-qPCR 
or by analyzing genes that display influence on COX-1 
and COX-2 gene expressions, such as TXB2, PGE2, and 
MMP. Table 2 presents the principal results found in the 
studies.
Discussion
Third molar surgery is a routine clinical procedure per-
formed at dental practices, and it has been the subject of 
studies evaluating the use of preoperative medications 
(NSAIDs) to minimize inflammatory events observed 
during the postoperative period (7). In fact, this clini-
cal model has been widely reproduced in translational 
researches aiming to evaluate protocols of medicines 
since 1976, when its validation in pharmacological 
studies was provided (24). The present systematic re-
view based on the PRISMA methodology reported rel-
evant data related to of oral surgery with evaluation of 
gene expression following removal of maxillary and 
mandibular third molars.
A considerable variety of methodologies were found 
to have been used for clinical and laboratory purposes, 
including the gene studied, the preemptive analgesic 
medication, the type of material collected for gene ex-
pression analysis, study periods, and the method for an-
alyzing gene-related mRNA. Since several methods to 
evaluate gene expression of COX or related genes was 
performed among the critically reviewed articles some 
difficulty was encountered in obtaining a standardized 
and reliable analysis. Of the eligible studies, there were 
three investigations that directly evaluated the COX 
genes (2,4,5), while the remaining studies used an in-
direct method to provide the evaluation. These articles 
analyzed TXB2 and PGE2 (4,13,23), MMP (20), or a set 
of genes including PLA, SOCS3, and IL-6 (21,22). 
These genes are involved in the inflammatory response, 
which is mediated by prostaglandins produced via cell 
membrane phospholipid-related arachidonic acid me-
tabolism. It can be triggered by two COX pathways. 
COX-1 is the isoform constitutively expressed which 
is involved in the regulation and homeostasis of physi-
ological processes, but is also active during the onset 
of acute inflammation. COX-2 is an inducible isoform 
produced in inflammatory and infectious processes, 
showing a direct relation with the increased produc-
tion of pro-inflammatory prostaglandins and cytokines 
such as PGE2, TNF-α, and IL-1β (3,9,22). PGE2 is re-
leased into inflamed tissues in order to sensitize affer-
ent nerve fiber terminals, increasing the nociceptive 
process and evoking hyperalgesia (13,23), while TNF-α 
exerts a remarkable range of effects, including activat-
ing lymphocytes, stimulating the synthesis of other 
proinflammatory cytokines such as IL-1β and IL-6, and 
triggering the production of prostaglandins. IL-1β also 
sensitizes nociceptors and causes hyperalgesia, acting 
to promote pain pathophysiology (3). mRNA related 
to COX-1 expression has a half-life of about 12–15 h 
while COX-2 mRNA has a shorter half-life of less than 
3.5 h, suggesting an intrinsic temporal link between 
tissue injury, COX-2 expression, and increased PGE2 
levels compared to COX-1 expression, which is respon-
sible for coagulation and directly linked to COX-1 ac-
tivity (4,13,23). In addition, matrix metalloproteinases 
(MMP) play an important role in the inflammation and 
is regulated by PGE2, serving as a reference for COX-2 
(21). Other genes that are also related to inflammation 
but scarcely studied are IL-6, SOCS3 and PLA, which 
may increase with inflammation, serving as indicative 
regulatory parameters for COX levels locally (22).
Ehrich et al. (23) evaluated COX isoform expression 
indirectly (TXB2 for COX-1 and PGE2 for COX-2) 
from blood samples and showed that rofecoxib was a 
potent selective COX-2 NSAID, exhibiting about 800 
times greater selectivity for COX-2 than COX-1, and it 
exhibited about 1000 times greater COX-2 selectivity 
in comparison with a non-selective NSAID (indometha-
cin). Furthermore, as previously confirmed by Lee et 
al. (4) in a study with gingival tissue samples, it was 
observed that TXB levels did not change significantly. 
In addition, it was demonstrated that COX-1-related ac-
tivity in the placebo and testing groups (rofecoxib and 
acetaminophen) showed no significant differences. The 
preoperative administration of these NSAIDs to indi-
viduals undergoing third molar surgeries resulted in 
suppression of PGE2 levels compared to the placebo 
group, highlighting the COX-2 selectivity pattern.
According to Kahn et al. (13), TXB2 gene expression is 
specifically related to the COX-1 isoform, while PGE2 
gene expression was highly associated with COX-1 lev-
els in a 60-min period following the onset of the inflam-
matory process and to COX-2 levels. In the latter study, 
COX-2 selectivity provided by celecoxib administered 
preemptively resulted in PGE2 gene suppression with-
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Authors Participants Study design Outcomes








- Rofecoxib showed a selectivity greater than 800-fold for COX-2 
with the use of CHO cells expressing human COX-1 and COX-2;
- LPS-stimulated prostaglandin E2 dose-concentration-dependent 
inhibition was observed with both rofecoxib and indomethacin;
- Indomethacin inhibited TXB2, which did not occur with rofecoxib 
even at concentrations of 1000 mg.
- Total pain relief over 6 hours after NSAID administration was 
similar between rofecoxib 50 mg and 500 mg doses, and 400 mg 
ibuprofen (p > 0.20). All drugs tested showed positive results hi-
gher than placebo (p < 0.001).




- Clinical trial. - The expression of COX-2 at 30, 60, and 120min (p < 0.05), and the COX-1 rate at 60 min presented a reduction (p < 0.05).







- Release of PGE2 was suppressed by ketorolac, rofecoxib and aceta-
minophen compared to placebo at 3h, coincident with increased gene 
expression of COX-2;
- The release of TXB2 was suppressed only by ketorolac;
- COX-2 gene expression remained elevated within 24 hours with 
continuous treatment with ketorolac and paracetamol;
- COX-1 gene expression was significantly down-regulated at 24h 
by ketorolac, rofecoxib, and acetaminophen.







- Rofecoxib showed increased MMP expression compared to ibupro-
fen and placebo.
- ANXA3, SOD2, SOCS3, and IL2 expresseion was increased in the 
rofecoxib group;
- IL6 and CCL2 expression was increased with the use of NSAIDs.







- Rofecoxib increased ANXA3, SOD2, SOCS3, and IL1RN expres-
sion, and suppressed cytokine signaling cascades in comparison 
with placebo;
- Rofecoxib and ibuprofen increased IL6 and CCL2 gene expression 
in comparison with placebo.








- PTGS1 expression slightly decreased (p<0.001) and PTGS2 expres-
sion markedly increased (p<0.001) at 2 to 4h after surgery;
- Ibuprofen and rofecoxib significantly increased COX-2 expression 
at 48-hour period (p <0.001 and <0.049, respectively).
-  G/G allele at the 765G>C nucleotide position in PTGS2 showed 
significant increase of PTGS2 expression (p=0.012) at 2 and 4h pe-
riod;
- Rofecoxib relief pain intensity in patients with G/G allele 48h 
after surgery compared with ibuprofen (p=0.008). 







- Celecoxib and ibuprofen showed a significant analgesic effect in 
comparison with placebo (p<0.01), and celecoxib efficacy was inter-
mediate between ibuprofen and placebo;
- A similar ratio was observed for suppression of prostaglandin E2 
at specific time points consistent with COX-2 expression (p <0.001);
- Ibuprofen consistently suppressed TBX2 levels at all study pe-
riods (p<0.05), while the effect of celecoxib did not differ from 
placebo.
Table 2. Characterization of the selected studies according to the sample number, study design, outcomes, and conclusion.
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out alteration of TXB2 levels during the postoperative 
period beyond 60 min. Ibuprofen, however, suppressed 
both PGE2 and TXB2 over both evaluated study peri-
ods, which is consistent with its dual COX-1/COX-2 in-
hibitory effects.
Clinically, several trials have shown that NSAIDs ame-
liorate the symptoms associated with third molar sur-
geries (3,6,7,10). On the basis of inflammation assess-
ments, MMP family-related genes have been linked 
with a decrease in the severity of the inflammatory pro-
cess when COX-2 selective drugs are prescribed to pa-
tients that underwent surgical removal. Wang et al. (21) 
showed that in samples of gingival tissue, MMPs play 
an essential role in acute inflammatory injury and their 
activity is regulated by COX-2 mediated PGE2 release. 
They reported a significant increase in MMP expression 
in a clinical study using rofecoxib in comparison to ibu-
profen and placebo, which may contribute to rofecoxib-
associated adverse effects: interference with the resolu-
tion of inflammation and onset of undesirable effects. In 
addition to the MMP results, other genes mediated by 
COX-2 expression and associated with the occurrence 
of inflammatory events i.e., the arachidonic acid path-
way, apoptosis/angiogenesis, cell adhesion, and signal 
transduction were also analyzed (21). Wang et al. (22) 
also observed that gene expression of ANXA3 (annexin 
3; involved in the regulation of inflammatory responses, 
cell differentiation and cytoskeletal protein interactions, 
associated with multiple human diseases); SOD2 (su-
peroxide dismutase 2: expressed in the central nervous 
system in several inflammatory conditions); SOCS3 
(suppressor of cytokine signalin 3, which regulates the 
signaling of cytokines or hormones, modulating the out-
come of autoimmune infections and diseases, as well as 
the underlying mechanisms); and IL1RN (IL1 receptor 
antagonist, associated with several markers of systemic 
inflammation) were increased in the group treated with 
rofecoxib. These were predictable results, since these 
genes are related to the inhibition of phospholipase A2 
after local trauma and decrease in cytokine signaling 
pathways. In addition, groups treated with rofecoxib 
or ibuprofen showed an increase in gene expression of 
the inflammatory mediators IL-6 (a cytokine involved 
in both the inflammatory and infection responses, and 
in the regulation of metabolic, regenerative, and neural 
processes), and CCL2, chemokine (C-C motif) ligand 2, 
(which is involved in neuroinflammatory processes and 
is present at the sites of tooth eruption and bone degra-
dation), after surgical trauma when compared to the pla-
cebo. These results emphasize that COX selectivity is 
involved not only in anti-inflammatory effects but also 
in the increase in pro-inflammatory cytokine levels and 
hence may play a role during the inflammatory process 
in local injuries, such as the third molar removal (22).
Regarding COX gene expression over time, Kahn et 
al. (5) performed a quantitative analysis of COX-1 and 
COX-2 isoforms in a clinical study of third molar ex-
traction. These authors observed that all samples used 
to evaluate COX-2 gene expression showed a very weak 
band at baseline assessment (51%). However, there was 
a significant, progressive increase in COX-2 expres-
sion at 30, 60, and 120 min after surgery. When COX-
1 expression was measured, a slight decrease was de-
tected at 30 min, a considerable reduction at 60 min, 
and a significant reduction compared to baseline at 120 
min. In fact, these findings related to the expression of 
COX-2 were expected, considering that no preemptive 
NSAIDs were used and that only the normal inflamma-
tory process was triggered by surgical extraction of a 
third molar. In the case of the COX-1 results, other stud-
ies that indirectly evaluated its expression supported 
these findings (4,13,21,22). Another study that quanti-
tatively described COX-1 and COX 2 gene expression 
was performed by Lee et al. (2), in which an increase in 
COX-2 and a decrease in COX-1 were observed at 2–4 
hours postoperatively, returning to pre-surgical values 
at 48 h after surgery. These findings suggest that acute 
injury resulting in inflammatory processes stimulates 
increased gene expression of COX-2 and transient in-
hibition of COX-1 expression. There was also a slight 
increase in the expression of IL-1β (2–4 h), PLA2 (2–4 
h and 48 h) and a decrease in PTGH levels (an enzyme 
encoded to degrade prostaglandins) over time (2). 
Postoperative pain was assessed in four translational 
studies that used a laboratory analysis in order to asses 
COX gene expression following third molar surgery 
(2,4,13,23). In the study performed by Ehrich et al. (23), 
the analgesic efficacies of rofecoxib and ibuprofen were 
postoperatively evaluated and significant reduction in 
pain perception in both of groups was found in compar-
ison to the placebo group; however, there was no statis-
tically significant difference between the NSAIDs. The 
time required for pain relief did not differ between the 
groups, but it was statistically significant in comparison 
to the placebo. The use of rescue analgesia during the 
two-hour postoperative period was reported by 75% of 
patients treated with placebo, whilst test groups (rofe-
coxib and ibuprofen) comprised 25% that received res-
cue drugs up to six hours after the surgical removal of 
the third molar, highlighting the efficacy of the NSAIDs 
in relieving pain postoperatively.
In the study of Lee et al. (4) that evaluated the preemp-
tive analgesic efficacy of rofecoxib, acetaminophen, 
and ketorolac compared with the placebo, there was a 
gradual increase in pain scores over the first three hours 
showing no statistically significant differences between 
the rofecoxib and acetaminophen groups or in com-
parison with the placebo group; however, preoperative 
ketorolac use delivered the best results with respect to 
pain relief over a two-hour study period together with 
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rescue medication intake and the cumulative effect of 
pain scores over the time in comparison with placebo. 
In contrast to acetaminophen, rofecoxib showed a sta-
tistically significant reduction of pain scores after two 
hours following the surgical procedure. The authors of 
this study also pointed that the results were consistent 
in relation to gene expression of TXB2 and PGE2. Lee 
et al. (2) showed that gene expression of COX isoforms 
was not the only factor supporting the observed anal-
gesic efficacy of rofecoxib and ibuprofen preemptively 
used. These authors investigated COX gene polymor-
phism and showed that in patients with the homozy-
gous alleles for COX-2 (G/G) there was a significant 
reduction in pain 48 h after administration of rofe-
coxib in comparison with that after administration of 
ibuprofen. In individuals with reduced expressivity of 
alleles (homozygous and heterozygous, C/C and G/C 
respectively), the opposite effect on pain relief at 48 h 
postoperative was observed and better pain scores were 
obtained with ibuprofen. Thus, these findings reinforce 
the importance of gene polymorphism in determining 
the efficacy of preemptive analgesic medication follow-
ing third molar surgeries.
In another investigation performed by Kahn et al. (13), 
it was shown that celecoxib and ibuprofen delivered 
better results in relieving pain postoperatively than the 
placebo group, which presented increasing pain inten-
sity over the studied periods. However, celecoxib did 
not differ from placebo regarding pain relief at certain 
times (120, 180, and 240 minutes). In contrast, ibupro-
fen resulted in pain scores consistently reducing over 
time.
Conclusions
In summary, third molar surgeries were associated with 
different COX-related gene expression patterns. Al-
though inflammatory events following the surgical pro-
cedure are associated with COX isoforms, it was found 
that data from preemptive analgesia studies are scarce, 
especially those correlating gene expression with clini-
cal parameters. The present findings were revealing 
in relation to the effect of selective and non-selective 
NSAIDs administered preoperatively with the aim of 
controlling the postoperative pain level. In the future, 
from a clinical perspective, identifying the molecular 
targets of a drug based on individual gene expression 
may be helpful in the delineation of specific, third molar 
surgery-related, preemptive analgesia protocols.
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